靶向FAP的新型双模态PET/荧光探针用于精准勾勒肿瘤边界的临床前与初步临床评估
研究合成靶向成纤维细胞活化蛋白(FAP)的双模态探针IRDye800CW-FAP-2286与IRDye800CW-3BP-3940,在HEK293T-FAP细胞与小鼠移植瘤模型中行PET与近红外二区荧光成像,并对切除肺组织行离体荧光验证。两种探针均显示高亲和力与高肿瘤特异性,IRDye800CW-3BP-3940表现优于IRDye800CW-FAP-2286,临床标本中与组织病理学高度一致。
要点
- IRDye800CW-FAP-2286与IRDye800CW-3BP-3940在体外对FAP阳性细胞均显示高亲和力。
- 体内PET显示两种探针均具有高肿瘤特异性,近红外二区荧光可准确显示肿瘤边界。
- IRDye800CW-3BP-3940表现优于IRDye800CW-FAP-2286,临床肺标本中与病理高度一致。
核心结论
- 研究开发并验证了整合PET与近红外荧光成像的新型双模态分子探针IRDye800CW-3BP-3940,可高特异性检测FAP阳性肿瘤并在切除标本中精准勾勒肿瘤边界。
研究设计与样本
- 将DOTA螯合剂引入由FAP-2286和3BP-3940与近红外荧光团IRDye800CW偶联而成的双模态FAP靶向探针,用于镓-68放射性标记。
- 在稳定表达FAP的HEK293T-FAP细胞和移植瘤小鼠模型中行体外与体内评估,采用PET与近红外二区荧光成像评估探针特异性及勾勒肿瘤边界的能力。
- 临床验证采用切除肺组织与探针离体孵育,以荧光成像识别肿瘤区域与边界,并经苏木精-伊红染色和FAP免疫组化验证。
主要发现
- IRDye800CW-FAP-2286与IRDye800CW-3BP-3940在体外对FAP阳性细胞均显示高亲和力。
- 体内PET成像显示两种探针均具有高肿瘤特异性。
- 体内与离体近红外二区荧光成像可准确显示肿瘤边界,IRDye800CW-3BP-3940表现优于IRDye800CW-FAP-2286。
- 临床标本中IRDye800CW-3BP-3940成功勾勒肿瘤区域,与组织病理学发现高度一致。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Accurate delineation of tumor margins and maximal safe resection are critical for successful curative oncologic surgery. However, fibroblast activation protein (FAP)-targeted probes suitable for fluorescence imaging remain limited. Here, we developed novel FAP-targeted fluorescent probes to accurately delineate tumor margins and enable rapid intraoperative identification of tumor boundaries in resected specimens. METHODS: DOTA chelator for radiolabelling with gallium-68 was incorporated into dual-modality FAP-targeted probes synthesised by conjugating FAP-2286 and 3BP-3940 with the near-infrared (NIR) fluorophore IRDye800CW. These probes were evaluated both in vitro and in vivo using HEK293T-FAP cells stably expressing FAP and xenograft mouse models. Positron emission tomography (PET) and (NIR-II) fluorescence imaging assessed the specificity and ability of probes to delineate tumor margins. For clinical validation, resected lung tissue was incubated ex vivo with the probes. Tumor regions and margins were identified using fluorescence imaging and subsequently validated by haematoxylin and eosin (H&E) staining and FAP immunohistochemistry. RESULTS: Both IRDye800CW-FAP-2286 and IRDye800CW-3BP-3940 exhibited high affinity for FAP-positive cells in vitro. PET imaging revealed high tumor specificity for both probes in vivo. In vivo and ex vivo NIR-II fluorescence imaging enabled accurate visualisation of tumor margins, with IRDye800CW-3BP-3940 exhibiting superior performance compared with IRDye800CW-FAP-2286. In the clinical specimen, IRDye800CW-3BP-3940 successfully delineated tumor regions with strong concordance to histopathological findings. CONCLUSION: We developed and validated a novel dual-modality molecular probe, IRDye800CW-3BP-3940, which integrated PET and NIR fluorescence imaging capabilities. This probe enabled highly specific detection of FAP-positive tumors and precise delineation of tumor margins in resected specimens.
引用
- Zhao L, Pang Y, Xu D, et al. Preclinical and pilot clinical evaluation of novel dual-modality pet/fluorescence probes targeting FAP for accurate tumor margin delineation. Eur J Nucl Med Mol Imaging. 2025. PMID: 40848055. doi:10.1007/s00259-025-07512-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。